Dr. Martens (LON:DOCS – Get Free Report) announced its quarterly earnings results on Thursday. The company reported GBX (0.90) EPS for the quarter, Digital Look Earnings reports. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%.
Dr. Martens Price Performance
Shares of Dr. Martens stock traded down GBX 8.34 during trading on Thursday, hitting GBX 73.26. 3,588,286 shares of the company were exchanged, compared to its average volume of 2,198,918. Dr. Martens has a fifty-two week low of GBX 43.02 and a fifty-two week high of GBX 100.87. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The firm has a 50 day moving average price of GBX 90.64 and a 200 day moving average price of GBX 80.35. The stock has a market capitalization of £707.92 million, a price-to-earnings ratio of 146.52, a P/E/G ratio of 6.40 and a beta of 0.11.
Insiders Place Their Bets
In other Dr. Martens news, insider Giles Wilson sold 30,000 shares of the firm’s stock in a transaction on Monday, September 1st. The stock was sold at an average price of GBX 91, for a total transaction of £27,300. Also, insider Ije Nwokori sold 298,675 shares of the business’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of GBX 90, for a total value of £268,807.50. In the last quarter, insiders have acquired 136,960 shares of company stock worth $12,460,163 and have sold 434,460 shares worth $39,131,400. 2.80% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on DOCS
About Dr. Martens
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
Featured Articles
- Five stocks we like better than Dr. Martens
- Buy P&G Now, Before It Sets A New All-Time High
- NVIDIA Just Proved the AI Boom Is Bigger Than Anyone Thought
- Trading Stocks: RSI and Why it’s Useful
- Why Target Stock May Keep Falling Despite a 5% Dividend Yield
- How to Invest in Biotech Stocks
- Is Tesla Setting Up for a Year-End Rebound—or a Collapse?
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
